Svetlana Ho

A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).

Thomas Powles, Alexandra Drakaki, Jeremy Yuen‐Chun Teoh et al. · Journal of Clinical Oncology · 2022 · 38 citations

Medicine, Oncology, Pharmacology +17

Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.

Thomas Powles, Michiel Simon Van Der Heijden, Ying Wang et al. · Journal of Clinical Oncology · 2025 · 35 citations

Medicine, Oncology, Surgery +16

A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States

Rebecca Levorson, Erica Christian, Brett Hunter et al. · PLoS ONE · 2021 · 33 citations · Full text

Medicine, Infectious Diseases, Pediatrics +14